A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.

Study summary

This study will assess the effectiveness of a natural nutraceutical in treating the known side effects of chemotherapeutic agents in cancer patients.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedChemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell) and Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo

Plus 1 other study approaches.

Who it may be forBreast Cancer · Lung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Mar 21, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Optimal Health Research

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 2
Sponsor: Optimal Health Research
Interventions being studied: Dietary Supplement: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell); Drug: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo; Drug: Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Chemotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Active breast cancer patients taking one of the studies listed drugs within the age range. Active lung cancer patients taking one of the studies listed drugs within the age range. Active prostate cancer patients taking one of the studies listed drugs within the age range. \-

Reasons someone may not be able to joinExclusion criteria

Anyone without the three types of cancer (breast cancer, lung cancer, prostate cancer) listed in inclusion criteria. \-

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Optimal Health ResearchSalt Lake City, Utah

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 21, 2025. Always confirm current availability with the study team.

View original record ↗